Clinical trial
A Pilot Study To Evaluate Patient Experience With the Somatostatin Analogs Octreotide Long Acting Release and Lanreotide During the Treatment of Advanced, Nonfunctional, Well Differentiated Neuroendocrine Tumors
NCT03289741 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Pilot Study To Evaluate Patient Experience With the Somatostatin Analogs Octreotide Long Acting Release and Lanreotide During the Treatment of Advanced, Nonfunctional, Well Differentiated Neuroendocrine Tumors
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- September 19, 2017
- Completion date
- April 10, 2023
- Enrollment
- 51 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.